Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Dutch study tracks COVID antivirals in High-Risk patients

NCT ID NCT05195060

First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 25 times

Summary

This study followed over 1,100 high-risk COVID-19 patients in the Netherlands who received new antiviral drugs or monoclonal antibodies. Researchers collected blood samples and nasal swabs over 90 days to see how the virus and the body's immune response changed during treatment. The goal was to learn which patients benefit most and to watch for new virus variants, not to test a new treatment directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Amsterdam University Medical Centre

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Amsterdam University Medical centre - VUMC

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Leiden universitair medisch centrum

    Leiden, 2333ZA, Netherlands

  • Radboud Universitair Medisch Centrum

    Nijmegen, 6525GA, Netherlands

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.